Abivax S.A.
Industry
- Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Technologies
- Molecular Diversity
- Pharmaceuticals
- Vaccines
Latest on Abivax S.A.
The years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial
Abivax has spent heavily on advancing obefazimod through late-stage trials for ulcerative colitis (UC) and is eagerly awaiting a readout to see whether its faith in the compound will translate into a
With a star pipeline candidate entering Phase III clinical trials for the treatment for ulcerative colitis, Abivax S.A. is in the midst of a corporate rework to be able to secure funding and ultimat
AstraZeneca PLC has discontinued its anti-IL-23 monoclonal antibody, brazikumab, for inflammatory bowel diseases (IBD) as the market and pipeline become increasingly crowded and following unavoidable